TEST (Tigecycline Evaluation Surveillance Trial)

Global Trial in 1245 MRSA isolates

Activity against MRSAwas more potent than all antimicrobial agents like imipenem, minocycline, linezolid and vancomycin

More senstivity

for Acinetobacter baumannii than Imipenem and other carbapenems

Highly active

Against enterobacteriaceae, regardless of the presence or absence of ESBLs.

Potent activity against vancomycin resistant enterococci and penicillin resistant Streptococcus pneumoniae

Excellent tissue/fluid penetration

Tigecycline(Tigeced) exhibits a rapid distribution phase after intravenous administration and a large apparent volume of distribution (568L).

In vitro protein binding in human plasma has been reported to be concentration-dependent and ranges from 71% at 0.1 mg/Lto 87% at 10 mg/L.

Proven efficacy

At par or better than existing options available.

Tigecycline(Tigeced) has shown comparable efficacy against levofloxacin, imipenem/cilastatin and vancomycin+aztreonam.

Appropriate choice for empirical monotherapy

In Community Acquired Pneumonia (CAP)

Tigecycline(Tigeced) has high intrapulmonary concentrations that exceed the MIC of most of the 90 respiratory pathogens (Staphylococcus aureus, penicillin-resistant Streptococus pneumoniae 7 and multidrug-resistant Enterobacteriaceae).